The purpose of this study is to assess surgical conversion rate and the immediate and long-term outcomes to patients who receive hypofractionated radiotherapy and AG combined with camrelizumab immunotherapy of Borderline Resectable/locally advanced pancreatic cancer.
Age:18 to 75 years old, male or female;
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1;
Tumor was located in the pancreas;
Pathological diagnosis was pancreatic ductal adenocarcinoma or acinar cell carcinoma;
Patients who did not meet these inclusion criteria;
Poor cognitive ability, inability to answer questions, inability to fill out questionnaires, or mental disorders;
The investigators think inappropriate.